SCHEMBL20093470

SCHEMBL20093470

Nc1cccc(Nc2cc(Cl)ncn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
EGFR P00533 7/20 0.50
AHR P35869 1/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
GFER P55789 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ERBB3 P21860 2/20 0.47
MKNK1 Q9BUB5 1/20 0.46
ERBB2 P04626 1/20 0.46
RET P07949 1/20 0.44
KDR P35968 1/20 0.44
SIRT7 Q9NRC8 1/20 0.44
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL691596 0.83 MEN1 (0.67) NPC1EGFRAHRKDM4EMEN1
SCHEMBL3952295 0.83 EGFR (0.66) NPC1EGFRKDM4EMEN1MAPT
Hydrochloric Acid SCHEMBL2173883 0.82 EGFR (0.64) NPC1EGFRKDM4EMEN1MAPT
SCHEMBL4663995 0.81 NPC1 (0.64) NPC1EGFRMEN1GAAMAPT
SCHEMBL857502 0.81 NPC1 (0.63) NPC1EGFRMEN1LMNAGAA
SCHEMBL4239725 0.81 AHR (0.47) EGFRAHRKDM4EMEN1LMNA
SCHEMBL12510600 0.81 NPC1 (0.51) NPC1EGFRMEN1MAPTKMT2A
SCHEMBL691533 0.81 EGFR (0.57) NPC1EGFRERBB3TNNI3K
SCHEMBL14959187 0.81 THRB (0.62) NPC1EGFRAHRKDM4EMEN1
SCHEMBL2279629 0.81 EGFR (0.59) NPC1EGFRERBB3MKNK1TNNI3K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3313530-B1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA FARBER CANCER INST INC (US) 2022-10-05 EP disclosed
US-20210315894-A9 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-10-14 US disclosed
US-20200338075-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-10-29 US disclosed
US-10695346-B2 4,6-pyrimidinylene derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-06-30 US disclosed
US-20180110778-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200338075-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF CDK3, CDK1, CDK14 NPC1 4304/4885EGFR 2020/4885AHR 4143/4885
US-10695346-B2 4,6-pyrimidinylene derivatives and uses thereof CDK3, CDK1, CDK14 NPC1 4304/4885EGFR 2020/4885AHR 4143/4885
US-20210315894-A9 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF CDK3, CDK1, CDK14 NPC1 4304/4885EGFR 2020/4885AHR 4143/4885
US-20180110778-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF CDKL4, CDKL5, PIP5K1A NPC1 4264/4885EGFR 2153/4885AHR 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.